Goodship, Tim H J

Machin, Sam

Taylor, C Mark

Wigmore, Stephen J

English

Atypical haemolytic uraemic syndrome (aHUS) is associated with a poor prognosis with regard to survival at presentation, recovery of renal function and transplantation. It is now established that aHUS is a disease of complement dysregulation with mutations in the genes encoding both complement regulators and activators, and autoantibodies against the complement regulator factor H. Identification of the underlying molecular abnormality in an individual patient can now help to guide their future management. In these guidelines we make recommendations for the investigation and management of aHUS patients both at presentation and in the long-term. We particularly address the role of renal transplantation alone and combined liver-kidney transplantation

?, ?

Edinburgh Research Explorer

19 The interactive factor H-atypical haemolytic uraemic syndrome mutation database and website: Update and integration of membrane cofactor protein and factor I mutations with structural models.

A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

An interactive web database of factor H-associated hemolytic uremic syndrome mutations: insights into the structural consequences of disease-associated mutations.

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Attempted treatment of factor H deficiency by liver transplantation.

Atypical haemolytic uraemic syndrome associated with a hybrid complement gene.

Atypical haemolytic uraemic syndrome.

Cobalamin C defect associated with hemolytic-uremic syndrome.

Combined kidney and liver transplantation for familial haemolytic uraemic syndrome.

Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.

Complement Factor I : a susceptibility gene for atypical hemolytic-uremic syndrome.

Deletion of complement factor H related genes CFHR1 and CFHR3 is associated with an increased risk of atypical hemolytic uremic syndrome.

Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Therapeutic Apheresis and Dialysis,

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation.

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome.

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology.

Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Hemolytic uremic syndrome in families.

Hemolytic uremic syndrome with recurrent episodes: an important subset.

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation.

Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.

Insights into hemolytic uremic syndrome: Segregation of three independent predisposition factors in a large, multiple affected pedigree.

Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation.

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome.

Ontogeny of complement regulatory proteins - concentrations of factor H, factor I, C4b-binding protein, properdin and vitronectin in healthy 16 children of different ages and in adults.

Outcome of renal transplantation in patients with non-shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background.

Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies.

Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor.

Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxinproducing Escherichia coli in stools.

Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.

Successful pretransplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome.

The role of platelets and platelet-derived growth factors in the pathogenesis of haemolytic-uraemic syndrome. In:

Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes.

Thomsen-Friedenreich antigen in haemolyticuraemic syndrome.

Thrombotic thrombocytopenic purpura and related disorders.

von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

C. Mark Taylor

Sam Machin

Stephen J. Wigmore

Tim H. J. Goodship

Crossref

Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

Abstract

Similar works

Full text

Available Versions

Edinburgh Research Explorer

Crossref